Quest Diagnostics Incorporated has been awarded several contracts by the U.S. Centers for Disease Control and Prevention $(CDC)$ to bolster testing and sustained laboratory readiness for emerging infectious diseases. These contracts, awarded in September 2024, include funding for the development of diagnostics to detect the Oropouche virus. The funding will ensure Quest Diagnostics maintains testing readiness, including having adequate supplies of equipment and chemical reagents, to rapidly mobilize a response if needed to safeguard public health. Additionally, Quest has launched the first commercially available diagnostic test for Avian Influenza A H5, supported by this funding.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: NY28798) on July 15, 2025, and is solely responsible for the information contained therein.